Cancer Bleeding Risk Index-Patients w/Malignant Lymphoma, Solid Tumors

Are you evaluating a patient with malignant lymphoma or solid tumor who has just started chemotherapy?

Yes

Gender of the patient

Male

Female

Does the patient have a history of bleeding previously?

Yes

Is there bone involvement by the neoplasm?

Yes

Is the primary site of the neoplasm in the genitourinary tract?

Yes

Is the primary site of the neoplasm in the genitourinary or gynecologic tract?

Yes

Baseline platelet count (before therapy)

Is the patient currently being treated with?

• penicillin or cephalosporin antibiotic?

Yes

• a tricyclic antidepressant or phenothiazine?

Yes

• an antihistamine?

Yes

• heparin?

Yes

Does the chemotherapy regimen include?

• cisplatin or carboplatin?

Yes

• carmustine or lomustine?

Yes

• dacarbazine?

Yes

• mitomycin C?

Yes

Select an appropriate answer to indicate the patient's functional level

Zubrod score (ECOG performance)

Evaluation

Results

Please fill out required fields.

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Therapy

Monitoring

Specialty

Objective

ICD-10

Bleeding Risk Index in Patients with Malignant Lymphoma or Solid Tumors

Purpose: To identify a patient with malignant lymphoma or solid tumor who is likely to bleed following chemotherapy using the bleeding risk index of Elting et al.